Lumiio is a global digital health company based in Calgary, Alberta, Canada that specializes in real-world data and evidence (RWD/RWE) platform technology and services. The company enables rare disease patient organizations, researchers, and life science companies to accelerate therapeutic development, clinical research, and market access to unlock the future of personalized patient outcomes. Lumiio’s advanced platform ingests virtually any type of health data with bi-directional sharing capabilities between patients and physicians, facilitating rapid and scalable patient data generation through organized patient communities.
Revolutionizing Health Outcomes Through Real-World Data and Evidence
Lumiio was founded in 2016 by Dr. Lawrence Korngut, MD (Neurologist) and Josh Lounsberry as a spinout from UCalgary Hotchkiss Brain Institute. The company’s mission is to solve the problem of lack of patient data prolonging R&D for new treatments, resulting in delayed access to life-saving treatments for patients and reduced market size and ROI for Pharma.
To tackle this problem, Lumiio has developed a 2-sided business model that enables rapid, scalable patient data generation through organized patient communities. The company facilitates a patient-to-pharma bridge to accelerate clinical trial recruitment and real-world data collection to support post-marketing surveillance (Phase IV) to expand access and reimbursement. The result is increased sustainability and value back to patients and patient organizations.
Exceptional Team and Experience in Global Data Programs
Lumiio has an exceptional team with significant global expertise and experience, including 12+ years from the Canadian Neuromuscular Disease Registry (CNDR) to Lumiio’s current data programs. The team has experience expanding to 60 countries for over 150 rare diseases and has over 250 data releases and publications from their registry work.
Boostrapped Growth and Future Plans
Lumiio is a bootstrapped company that achieved $1.1M in revenue in 2021, with 100% YoY growth in the last 3 years. The company is currently raising $2.5M seed capital to accelerate product development and market expansion. The current focus is on clinical data, patient-reported data, and wearables.
Conclusion
Lumiio is a game-changer in the healthcare industry, providing real-world data and evidence (RWD/RWE) platform technology and services that enable researchers, patients, and Pharma to accelerate health outcomes. The company’s 2-sided business model facilitates rapid, scalable patient data generation through organized patient communities and provides sustainability and increased value back to patients and patient organizations. With an exceptional team and significant global experience, Lumiio is poised to revolutionize health outcomes and unlock the future of personalized patient outcomes.
Website: https://www.lumiio.com/
Twitter: https://twitter.com/Lumiio_Inc
Facebook: https://www.facebook.com/Lumiio.Inc
LinkedIn: https://www.linkedin.com/company/lumiio-inc/
Looking to amplify your brand’s impact in Canada’s thriving startup and investment sector? Join the league of innovators, leaders, and decision-makers making a difference through Canada Venture News. Engage with our audience of startup founders, investors, and executives through sponsored articles and partnerships. Discover more on our Promotion & Sponsored Articles page or email us directly at [email protected]. Let’s shape your story together.
